From ‘party drug’ to PTSD treatment: ATAI launches EmpathBio to develop MDMA-based therapy

August 24, 2020 Articles 9:00 am

Treatment for post-traumatic stress disorder (PTSD) varies from patient to patient and can combine different kinds of therapy and drugs, including anti-anxiety meds and antidepressants. Problem is, the only drugs approved for PTSD don’t work for everyone, and even when they do, they don’t work perfectly and come with side effects.

 

JOIN THE ATAI #INSIGHTNETWORK

Receive the latest news on ATAI and innovations in the space.

Email
submit